Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 vs Chemotherapy in High-risk Non-muscle-invasive Bladder Cancer (MoonRISe-3)
NCT06919965Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 15
01
Overview
A Phase 3 trial of Erda-iDRS in non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Sep 2025; status: recruiting.
02
Drugs
Erda-iDRS
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06919965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919965.